US EditionLilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push
- Eli Lilly And Co has agreed to acquire Verve Therapeutics for up to $1.3 billion to enhance cardiac care.
- Lilly's offer includes $10.50 per share in cash, totaling approximately $1.0 billion plus contingent rights worth up to an additional $3.00 per share.
- The acquisition aims for lifelong cardiovascular risk reduction through Verve's genetic medicines.
- The transaction is expected to close in the third quarter of 2025.
Insights by Ground AI
Does this summary seem wrong?
40 Articles
40 Articles
All
Left
5
Center
16
Right
3
Eli Lilly is in the spotlight after entering into advanced conversations to acquire Verve Therapeutics, an innovative startup in the field of genetic editing.According to the original Financial Times report, the deal could reach up to $1.3 billion.This strategic move marks a significant step in Eli Lilly's expansion into the biotechnology market.Details of the possible dealThe news came to light on Monday, when the Financial Times, backed by fam…
Coverage Details
Total News Sources40
Leaning Left5Leaning Right3Center16Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 21%
C 67%
13%
Factuality
To view factuality data please Upgrade to Premium
